ArticleDiabetes, obesity & metabolism2021
Semaglutide single-dose pen-injector: Post hoc analysis of summative usability testing for weight management.
Article in Diabetes, obesity & metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 6 citations in OpenAlex.
- Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial.Diabetes, obesity & metabolism · 2022Trial
- Effect of Semaglutide and Empagliflozin on Pulmonary Structure and Proteomics in Obese Mice.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Comparison of the injection-site experience of semaglutide in a single-dose and a multidose pen-injector.Diabetes, obesity & metabolism · 2022Article
- Metformin Inhibits Lipid Droplets Fusion and Growth via Reduction in Cidec and Its Regulatory Factors in Rat Adipose-Derived Stem Cells.International journal of molecular sciences · 2022Article
- Effects of Semaglutide on Cardiac Protein Expression and Cardiac Function of Obese Mice.Journal of inflammation research · 2022Article
- Semaglutide single-dose pen-injector: Post hoc analysis of summative usability testing for weight management.Diabetes, obesity & metabolism · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Subcutaneous semaglutide, at a 2.4 mg once-weekly maintenance dose, is approved in the United States for weight management in individuals with a body mass index (BMI) of 30 kg/m
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.